EUCTR2018-002248-95-SK进行中（未招募）1 期
Multi-centre, randomised, double blind, placebo-controlled, parallel, phase III study to assess the safety, tolerability and efficacy of bilastine ophthalmic solution 0.6% in adults - Bilastine ophthalmic solution in adults
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 300
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Male or female patients aged 18 years and above.
- •2. Documented history of AC before V1a.
- •3. Documented positive skin prick test and/ or positive validated IgE test to perennial allergen (e.g. cat dander, dog dander, dust mites and/or cockroach) or to seasonal allergen (e.g. grass, ragweed, and/ or tree pollen) within 6 months before V1a or a positive skin prick test at V1a.
- •4. Signs and symptoms of AC, i.e. tearing, itching and redness, that are likely to continue for the next weeks. Minimum score of four on an 11-item numeric rating scale in at least one of three categories at V1a and V2a.
- •5. Compliant use of e-diary during the screening period (from V1a to V2a).
- •6. Willing to comply in all aspects of the study, including
- •a) use of IMP from V2a to V4a
- •b) attending scheduled visits and completing telephone interviews.
- •7. Written informed consent
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 270
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 30
排除标准
- •1. History of known contraindications or sensitivities to the use of the IMP or any of its components.
- •2. History of intraocular surgery or planned surgery during study participation and within 2 weeks after follow-up.
- •3. History of ocular trauma (within the previous 6 months before V1a).
- •4. History or clinical evidence of ocular herpes simplex or ocular herpes zoster infectious disease.
- •5. History of any clinically significant external ocular disease within 30 days before V1a.
- •6. Presence of dry eye, active blepharitis, active meibomian gland dysfunction, active rosacea affecting the ocular surface/lid margin, active or chronic follicular conjunctivitis, preauricular adenopathy, or any other ocular or periocular abnormality that may affect study outcome.
- •7. Known history of recurrent corneal erosion syndrome (idiopathic or secondary to dry eye).
- •8. History of treatment failure to topical antihistamines.
- •9. Prior (within 2 years before V1a), current or anticipated anti-allergy immunotherapy.
- •10. Prior (within 4 weeks before V1a), current or anticipated corticosteroid treatment (systemic or local; in case of depot-corticosteroids: within 6 weeks before V1a).
- •11. Prior (within 1 week before V1a), current or anticipated use of any ophthalmic agents (including artificial tears), except IMP (starting at V2a).
- •12. Wearing of contact lenses during study participation.
- •13. Prior (within 2 weeks before V1a), current or anticipated systemic or intranasal treatment for allergic rhinitis.
- •14. Persons committed to an institution by virtue of an order issued either by the judicial or other authorities.
- •15. For women: Pregnancy or breast-feeding. Women of childbearing potential unable or unwilling to undergo pregnancy test(s) and practice acceptable contraceptive measures. Acceptable methods for women are surgical intervention (e.g. bilateral tubal occlusion), spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, true sexual abstinence (i.e. when this is in line with the preferred and usual lifestyle of the patient) and vasectomised male partner, provided that he is the sole partner of that patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception.
- •16. Patient has received an investigational drug (including investigational vaccines) or used an invasive investigational medical device within 30 days before V1a or is currently enrolled in an investigational interventional study.
研究者
相似试验
进行中（未招募）
1 期
Trial investigating the safety, tolerability and efficacy of bilastine eye drops 0,6% in adults in comparison with placeboEUCTR2018-002248-95-PLFAES FARMA S.A.300
进行中（未招募）
1 期
Trial investigating the safety, tolerability and efficacy of bilastine eye drops 0,6% in adults in comparison with placeboEUCTR2018-002248-95-HUFAES FARMA S.A.300
进行中（未招募）
1 期
Trial investigating the safety, tolerability and efficacy of bilastine eye drops 0,6% in adults in comparison with placeboEUCTR2018-002248-95-LTFAES FARMA S.A.300
进行中（未招募）
1 期
Clinical trial to assess the safety, tolerability and efficacy of Bilastine eye drops in children.EUCTR2020-002098-86-ESFAES FARMA, S.A.150
进行中（未招募）
不适用
Multicentre, randomised, double-blind, placebo-controlled clinical study to assess the efficacy and safety of UroVaxom in chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) - Uro-Vaxom in patients with chronic prostatitis and chronic pelvic pain syndromeChronic prostatitis and chronic pelvic pain syndromeMedDRA version: 9.1Level: LLTClassification code 10009109Term: Chronic prostatitisMedDRA version: 9.1Level: LLTClassification code 10064189Term: Chronic pelvic pain syndromeEUCTR2007-004609-85-PTOM PHARMA200